Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Clinical trial NCT04939701 · TERMINATED
Trial details
- NCT number
- NCT04939701
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-23
- Primary completion
- 2023-06-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.